Disruptive 3D Bioprinting
Can you imagine zero wait times for an organ transplant? This may soon be possible, thanks to the work being done by the pioneering biotech company, Next Big Innovation Labs (NBIL). It is making exceptional use of disruptive 3D Bioprinting technology to revolutionise pharmaceutical, clinical and cosmetic Research and Development (R&D).
NBIL’s proprietary printer, Trivima, is set to transform many traditional areas of medical research and practice, like bone regeneration, wound healing and new material development. It all boils down to NBIL’s vision which, according to Alok Medikepura Anil, NBIL’s Co-founder & Director, is “to empower the global medical community by creating transplantable organs in the laboratory”.
NBIL’s proprietary 3D Bioprinting technology has opened up remarkable possibilities for numerous interdisciplinary applications. It also allows for quicker and more efficient drug testing along with the creation of customised treatments and therapies. Integrating 3D Bioprinting technology into different industries helps in eliminating the need for animal or human testing, a concern that many companies are still grappling with today.
NBIL aims at creating a paradigm shift in the traditional R&D domain by partnering with inventive companies to develop Biotechnology and Bio-automation hardware. “NBIL, with its 3D Bioprinting platform, expertise, collaborations, and products, will enable the industry to leapfrog ahead”, says Anil. One of its long-term goals is to continually create ground-breaking products for the medical R&D community in India and abroad. It opened its second business office in Germany in August 2018.
“Our lab works at the intersection of engineering and biotechnology”, says Anil. This is evident, with NBIL having partnered with professionals in the field of medical surgery, to develop novel applications for supporting Maxillofacial surgeons in their work. NBIL’s use of 3D Bioprinting technology has helped medical professionals plan highly complex surgeries far more accurately than before.
The company is geared-up to continue innovating in 2019, with its soon-to-be-launched product, Innoskin, a 3D Bio-oriented skin tissue which can be used in place of actual human tissue in testing activities by FMCG and pharmaceutical companies. Developed in-house, NBIL claims that Innoskin will provide a viable and ethical option for the R&D needs of various companies.
Some awards and achievements of NBIL include getting recognised under the Startup India Scheme in 2016, winning the India Innovation Growth Program 2.0 in 2017, being judged the top startup at BioAsia 2018 and getting selected for Merck Pharmaceutical’s Accelerator Program at Darmstadt, Germany in 2018.